These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 12510660)
1. A dearth of groundbreaking data at 14th international conclave of HIV medical community. MacDougall DS IAPAC Mon; 2002 Oct; 8(10):276-82. PubMed ID: 12510660 [No Abstract] [Full Text] [Related]
2. When to start, when to STI (or, groping for the golden moment). Mascolini M IAPAC Mon; 2001 Apr; 7(4):114-7, 120-31. PubMed ID: 11700605 [No Abstract] [Full Text] [Related]
3. Impaired CD4+ cell recovery during antiretroviral therapy in patients with HIV resistance mutations. Sühs KW; Stoll M; Diem R; Schmidt RE; Heiken H Arch Virol; 2012 Mar; 157(3):433-40. PubMed ID: 22179846 [TBL] [Abstract][Full Text] [Related]
4. Intermediate highly active antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance mutations. Raffa JD; Tossonian HK; Grebely J; Petkau AJ; DeVlaming S; Conway B J Acquir Immune Defic Syndr; 2008 Mar; 47(3):397-9. PubMed ID: 18398974 [No Abstract] [Full Text] [Related]
5. Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia. Pujades-Rodríguez M; Schramm B; Som L; Nerrienet E; Narom P; Chanchhaya N; Ferradini L; Balkan S Trop Med Int Health; 2011 Feb; 16(2):205-13. PubMed ID: 21087376 [TBL] [Abstract][Full Text] [Related]
7. Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy. MacArthur RD; Perez G; Walmsley S; Baxter JD; Mullin CM; Neaton JD; ; HIV Clin Trials; 2005; 6(3):127-35. PubMed ID: 16192247 [TBL] [Abstract][Full Text] [Related]
8. [New biological monitoring of HIV infection]. Morand-Joubert L Rev Prat; 1998 Mar; 48(5):472-7. PubMed ID: 9781107 [No Abstract] [Full Text] [Related]
9. Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. Phillips AN; Staszewski S; Lampe F; Youle MS; Klauke S; Bickel M; Sabin CA; Doerr HW; Johnson MA; Loveday C; Miller V; ; J Infect Dis; 2002 Oct; 186(8):1086-91. PubMed ID: 12355358 [TBL] [Abstract][Full Text] [Related]
10. Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy. Sarmati L; Nicastri E; Montano M; Dori L; Buonomini AR; d'Ettorre G; Gatti F; Parisi SG; Vullo V; Andreoni M J Med Virol; 2004 Apr; 72(4):511-6. PubMed ID: 14981751 [TBL] [Abstract][Full Text] [Related]
11. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)]. Panel de expertos de GESIDA y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714 [TBL] [Abstract][Full Text] [Related]
12. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy. Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A; J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976 [TBL] [Abstract][Full Text] [Related]
13. [Highly active initial therapy without resistance development. Even after 6 years still effective HIV therapy]. MMW Fortschr Med; 2005 Apr; 147 Spec No 1():54-5. PubMed ID: 16385876 [No Abstract] [Full Text] [Related]
14. Suppression of hepatitis C virus replication is maintained long term following HAART therapy, in an individual with HCV/HIV co-infection. Torti C; Barnes E; Quiros-Roldan E; Puoti M; Carosi G; Klenerman P Antivir Ther; 2004 Feb; 9(1):139-42. PubMed ID: 15040546 [No Abstract] [Full Text] [Related]
15. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK; MMWR Recomm Rep; 2002 May; 51(RR-7):1-55. PubMed ID: 12027060 [TBL] [Abstract][Full Text] [Related]
16. Averting the evolution of drug resistance. Kieffer T; Siliciano R Hopkins HIV Rep; 2004 Jul; 16(4):9-10. PubMed ID: 15386837 [No Abstract] [Full Text] [Related]
17. Raltegravir/nevirapine dual therapy at reduced doses as 'maintenance' treatment in virally suppressed HIV-infected patients. Lanzafame M; Lattuada E; Rigo F; Nicole S; Cucchetto G; Vento S AIDS; 2015 Aug; 29(13):1722-3. PubMed ID: 26372286 [No Abstract] [Full Text] [Related]
18. Mega-HAART: preliminary results and correlation with baseline resistance. Rottmann C; Miller V; Staszewski S Antivir Ther; 1999; 4 Suppl 3():93-4. PubMed ID: 16021879 [TBL] [Abstract][Full Text] [Related]
19. Mutation and control of the human immunodeficiency virus. Stengel RF Math Biosci; 2008 Jun; 213(2):93-102. PubMed ID: 18439629 [TBL] [Abstract][Full Text] [Related]
20. Drug resistance and treatment of experienced patients. Gallant JE Hopkins HIV Rep; 2003 Mar; 15(2):8-9. PubMed ID: 12739503 [No Abstract] [Full Text] [Related] [Next] [New Search]